Literature DB >> 12910556

Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study.

Angelo Ravelli1, Carolina Duarte-Salazar, Silvia Buratti, Andreas Reiff, Bram Bernstein, Maria Rocio Maldonado-Velazquez, Rosalia Beristain-Manterola, Nobuaki Maeno, Syuji Takei, Valeria Gerloni, Charles H Spencer, Polyxeni Pratsidou-Gertsi, Nicolino Ruperto, Angela Pistorio, Alberto Martini.   

Abstract

OBJECTIVE: To investigate the prevalence of cumulative organ damage in patients with juvenile-onset systemic lupus erythematosus (SLE) and its association with demographic and clinical variables, medication use, and quality of life.
METHODS: The occurrence of organ system damage, as measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI), was determined for 387 patients consecutively enrolled in pediatric rheumatology centers from Europe, the US, Mexico, and Japan. Risk factors for damage included demographic variables; clinical manifestations at diagnosis; previous corticosteroid, immunosuppressive, and antimalarial therapies; disease activity; and quality of life.
RESULTS: Overall, 195 (50.5%) patients had damage within a mean of 5.7 years after disease onset. Renal (21.8%) and neuropsychiatric (15.8%) system involvement were observed most frequently, followed by musculoskeletal (11.7%), ocular (10.9%) and skin (9.6%) system involvement, with a mean SDI score of 1.1. In multivariate models, the occurrence of neuropsychiatric manifestations at diagnosis, a longer disease duration, and a greater number of intravenous cyclophosphamide pulses showed the strongest association with the presence of damage.
CONCLUSION: We found evidence of cumulative organ damage, as measured by the SDI, in half of the patients with juvenile-onset SLE. Damage was significantly more likely in patients who had experienced neuropsychiatric manifestations at diagnosis, had a longer disease duration, and had received more intravenous pulses of cyclophosphamide.

Entities:  

Mesh:

Year:  2003        PMID: 12910556     DOI: 10.1002/art.11205

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  34 in total

1.  Assessment of condyle, masseter and temporal muscles volumes in patients with juvenile systemic lupus erythematosus: A cross-sectional study.

Authors:  Sandra Lucia Golin; Nailu Angélica Sinicato; Karyna Valle-Corotti; Acácio Fuziy; Ana Carla Nahas-Scocate; Simone Appenzeller; Andre Luiz Ferreira Costa
Journal:  J Oral Biol Craniofac Res       Date:  2017-05-16

2.  Growth Pattern in Children with Systemic Lupus Erythematosus.

Authors:  Eiman Abdalla; Lakshamanan Jeyaseelan; Irfan Ullah; Reem Abdwani
Journal:  Oman Med J       Date:  2017-07

3.  Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study.

Authors:  Artemis Koutsonikoli; Maria Trachana; Anna-Bettina Heidich; Vasiliki Galanopoulou; Polyxeni Pratsidou-Gertsi; Alexandros Garyphallos
Journal:  Rheumatol Int       Date:  2015-01-14       Impact factor: 2.631

Review 4.  Prevalence and burden of pediatric-onset systemic lupus erythematosus.

Authors:  Sylvia Kamphuis; Earl D Silverman
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

Review 5.  A review on SLE and malignancy.

Authors:  May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-10       Impact factor: 4.098

6.  Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.

Authors:  Tünde Tarr; Gábor Papp; Nikolett Nagy; Edina Cserép; Margit Zeher
Journal:  Clin Rheumatol       Date:  2016-11-26       Impact factor: 2.980

7.  Evaluation of quality indicators and disease damage in childhood-onset systemic lupus erythematosus patients.

Authors:  Julia G Harris; Kristyn I Maletta; Evelyn M Kuhn; Judyann C Olson
Journal:  Clin Rheumatol       Date:  2016-12-24       Impact factor: 2.980

8.  Intravenous cyclophosphamide--resistant systemic lupus erythematosus in Arizona.

Authors:  Mehul P Dixit; Erika Bracamonte; Naznin Dixit
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

9.  Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.

Authors:  Lisa G Rider; Peter A Lachenbruch; Jason B Monroe; Angelo Ravelli; Imelda Cabalar; Brian M Feldman; Maria L Villalba; Barry L Myones; Lauren M Pachman; Robert M Rennebohm; Ann M Reed; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2009-11

10.  Influence of gender and age of onset on the outcome in children with systemic lupus erythematosus.

Authors:  Sulaiman M Al-Mayouf; Abdullah Al Sonbul
Journal:  Clin Rheumatol       Date:  2008-04-18       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.